Get the Stockscreener App
63.82
1.01%
0.64
After Hours:
64.09
0.27
+0.42%
Boston Scientific Corp stock is traded at $63.82, with a volume of 11.81M.
It is up +1.01% in the last 24 hours and down -7.68% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$63.18
Open:
$63.5
24h Volume:
11.81M
Relative Volume:
0.73
Market Cap:
$94.85B
Revenue:
$20.08B
Net Income/Loss:
$2.89B
P/E Ratio:
32.91
EPS:
1.9391
Net Cash Flow:
$3.66B
1W Performance:
+3.17%
1M Performance:
-7.68%
6M Performance:
-33.69%
1Y Performance:
-32.30%
1-Day Range:
$63.14
$64.48
1-Week Range:
$60.59
$64.48
52-Week Range:
$60.59
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
63.82 | 91.83B | 20.08B | 2.89B | 3.66B | 1.9391 |
ABT
Abbott Laboratories
|
101.05 | 174.29B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
345.88 | 129.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
88.12 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
EW
Edwards Lifesciences Corp
|
78.20 | 44.90B | 6.07B | 1.06B | 1.34B | 1.8063 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific Corp. stock (US10117L1017): Is medtech innovation strong enough to unlock new upsi - AD HOC NEWS
BOSTON SCIENTIFIC CORPORATION (BSX) DEADLINE ALERT Bernstein Liebhard LLP Reminds Boston Scientific Corporation Investors of Upcoming Deadline - TMX Newsfile
Fund Update: 486,715 BOSTON SCIENTIFIC (BSX) shares added to Bank Pictet & Cie (Europe) AG portfolio - Quiver Quantitative
Faruqi & Faruqi, LLP Highlights Class Action Against Boston Scientific (BSX) and Upcoming Lead Plaintiff Deadline of May 4, 2026 - marketscreener.com
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
Portnoy Law Firm Announces Class Action on Behalf of Boston Scientific Corporation Investors - GlobeNewswire
BSX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
Boston Scientific Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
Boston Scientific Corp. stock (US10117L1017): Is its medtech innovation edge strong enough to drive - AD HOC NEWS
BSX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - ChartMill
Why Boston Scientific's big dip could be a bigger opportunity - MSN
BSX Price History for Boston Scientific Corp Stock - Barchart.com
Boston Scientific (BSX) Receives FDA Clearance for Asurys Fluid Management System - Insider Monkey
Boston Scientific Corp. stock underperforms Thursday when compared to competitors - MarketWatch
ROSEN, A RANKED AND LEADING FIRM, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
BOSTON SCIENTIFIC CORPORATION (BSX) DEADLINE ALERT - GlobeNewswire
Boston Scientific Corp. stock rises Wednesday, still underperforms market - MarketWatch
Boston Scientific Faces Class Action Lawsuit from Shareholders - Intellectia AI
BSX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Deals tracker: Orlando Health to acquire Alabama health system - Modern Healthcare
Boston Scientific Neuromodulation Lawsuit Claims Spinal Cord Stimulator Exacerbated Chronic Pain - AboutLawsuits.com
BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit - Barchart.com
Fidelity Advisor Global Capital Appreciation Fund's Boston Scientific Corp(BSX) Holding History - GuruFocus
Boston Scientific (BSX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Boston Scientific Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
BOSTON SCIENTIFIC CORPORATION (BSX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Boston Scientific Corporation Investors of Upcoming Deadline - TMX Newsfile
Leerink Reiterates Outperform on Boston Scientific (BSX) After CHAMPION-AF Readout - Insider Monkey
Boston Scientific stock hits 52-week low at 61.23 USD By Investing.com - Investing.com Australia
Boston Scientific stock hits 52-week low at 61.23 USD - Investing.com
Boston Scientific Corp (NYSE:BSX) Offers Affordable Growth for Value-Conscious Investors - ChartMill
Boston Scientific Corp. Stock Plummets to New 52-Week Low at USD 60.91 - Markets Mojo
Boston Scientific Corp. stock: Down 35% but analysts see rebound potential - AD HOC NEWS
Boston Scientific (BSX) Price Target Lowered by Evercore ISI Gro - GuruFocus
Boston Scientific closes buyout of Valencia Technologies - MedTech Dive
BSX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
Piper Sandler maintains Boston Scientific stock rating after device feedback - Investing.com
Piper Sandler maintains Boston Scientific stock rating after device feedback By Investing.com - Investing.com India
Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Nike, Boston Scientific, And Sysco Are Among Top 10 Large Cap Losers Last Week (March 30-April 2): Are th - Benzinga
Boston Scientific Corporation (BSX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Boston Scientific Corp (MIL:1BSX) Bonds - GuruFocus
BSX Stockholders Have Opportunity to Lead Boston Scientific Corporation Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Boston Scientific Corporation (BSX) stock price, news, quote and history - Yahoo Finance Singapore
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Boston Scientific beats Q4 estimates, shares dip slightly - Investing.com
Boston Scientific Corp. Stock: Strong Growth in Medtech Amid Evolving Healthcare Demands - AD HOC NEWS
Boston Scientific completes acquisition of California bladder treatment company - Worcester Business Journal
BSX Shareholders Have Opportunity to Lead Boston Scientific Corporation Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
INVESTOR DEADLINE: Boston Scientific Corporation (BSX) - GlobeNewswire
RBC Capital reiterates Boston Scientific stock rating on growth outlook By Investing.com - Investing.com India
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):